Amarin Raises $104.9 Mln Through ADS Offering - interesting facts

Biopharmaceutical company Amarin Corp.Tuesday said it completed the previously announced underwritten public offering of American Depositary Shares or ADSs to the public at a price of $7.60 per ADS.
The company said, due to the exercise in full of the underwriters' over-allotment option, it sold a total of 13.80 million ADSs in the offering for an aggregate public offering amount of approximately $104.9 million.
The company received approximately $100.2 million of net proceeds from the offering, after deducting the underwriting discount and estimated expenses of the offering payable by the company.
Amarin expects to use the net proceeds to prepare for the commercialization of AMR101, file a New Drug Application and for working capital and general corporate purposes.